Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Down 7.6% in November: Crecon Report
January 14, 2015
- Daiichi Sankyo Reaches Settlement with US DOJ Following Investigation of Promotional Activities; to Pay US$39 Million
January 14, 2015
- GSK, Nippon Kayaku to End Copromotion of Cancer Drug Tykerb
January 13, 2015
- Otsuka, Fuso to Terminate Cancer Vaccine Deals with OncoTherapy
January 13, 2015
- FDA Approves Edoxaban for AF, VTE: Daiichi Sankyo
January 13, 2015
- GSK Japan Unit to Cut Jobs amid Global Restructuring Move
January 9, 2015
- FDA Accepts sNDA for Aptiom to Treat Partial-Onset Seizures
January 9, 2015
- Takeda Begins PII/III, PIII Studies of Rasagiline
January 9, 2015
- Kyowa Kirin Licenses Anticancer Drug from Syndax in Japan and South Korea
January 9, 2015
- Leading Generic Makers Disclose FY2013 Payments to Healthcare Professionals
January 8, 2015
- Celgene Applies for Additional Indication of Untreated Multiple Myeloma for Revlimid
January 8, 2015
- Hospira’s Oxaliplatin Generics Approved for Unresectable Pancreatic Cancer
January 8, 2015
- Takeda’s Potassium-Competitive Acid Blocker Approved in Japan
January 7, 2015
- Perampanel Meets Primary Endpoint in PIII Study for Asian Patients: Eisai
January 7, 2015
- Janssen Obtains Approval of Anti-HIV Drug Prezista Tablets 600 mg
January 7, 2015
- Taiho Obtains Approval of Double-Bag Formulation of Zosyn
January 7, 2015
- NBI Receives Approval for SGLT-2 Inhibitor Jardiance
January 6, 2015
- Takeda to Terminate License Agreement with AMAG for Iron Deficiency Anemia Treatment Ferumoxytol
January 6, 2015
- Sumitomo Dainippon to Reorganize Production Bases to Create Efficient, Low-Cost Production System
January 6, 2015
- AnGes MG Changes Development Strategy for NF-κB Decoy Oligo
January 5, 2015
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…